News analysis

Capitalising on China's upcoming biotech boom

As early opportunities beckon, note risks like high failure rates and long gestation periods

Ageing societies are now translating into higher national healthcare bills the world over.

In Asia, medical cost inflation is further compounded by rapidly rising incidences of non-communicable diseases (NCDs), including hypertension and cancer, in part from the region's swift urbanisation rates.


Thank you for reading The Straits Times

You have reached one of our Premium stories. To continue reading, get access now or log in if you are a subscriber.

What is Premium?

A version of this article appeared in the print edition of The Straits Times on August 06, 2018, with the headline 'Capitalising on China's upcoming biotech boom'. Print Edition | Subscribe